Rx News For Physicians Archive

2007

MDeNews™  June 2007
Brand v. Generic Antidepressants for the Treatment of Depression: What Does the Evidence Really Say?
June 27, 2007

Safety Information - Ortho Evra© and desogestrel-containing Oral Contraceptives
Find out what the FDA analysis of Ortho Evra and desogestrel-containing contraceptives concluded.
March 30, 2007

MDeNews™ March 2007
The ADOPT Study: Implications for the Choice of Initial Oral Hypoglycemic Therapy

Safety Information - Ortho Evra© and desogestrel-containing Oral Contraceptives
Find out what the FDA analysis of Ortho Evra and desogestrel-containing contraceptives concluded.
March 30, 2007

Generics First – Statin Program
In just the last year, high-quality statin generics that are able to provide up to 40% LDL-C lowering have become available. 
February 2, 2007

MDeNews™ January 2007
In response to requests for clinical updates, generic medication release dates and special member program changes we’ve developed MDeNews™.  To receive this quarterly electronic newsletter send an email to MDeNews@regence.com.  Please include the provider’s: (1) name; (2) email address; and (3) contact phone number.  Providers may also request the newsletter by calling 1 (877) 356-7763 and leaving the above information.
January 11, 2007

2006

FDA Alert - "At-Home" Genetic Tests May Lack Scientific Validity
Direct-to-consumer marketed genetic tests may lack scientific validity and provide questionable results.
August 8, 2006

The Regence Group Selects McKesson Specialty as Primary Specialty Pharmacy Provider
McKesson Specialty, a subsidiary of McKesson Corporation, announced today it has been selected by The Regence Group as the primary specialty pharmacy provider for its nearly 3 million covered lives.
April 4, 2006

RegenceRx has selected McKesson Specialty, a subsidiary of McKesson Corporation, as primary specialty pharmacy provider
RegenceRx has selected McKesson Specialty, a subsidiary of McKesson Corporation, as the primary specialty pharmacy provider for its nearly 3 million covered lives. McKesson Specialty will replace Regence's current specialty pharmacy vendor.
March 31, 2006

2005

MedWatch – Strattera and Increased Risk of Suicidal Thinking
The U.S. Food and Drug Administration (FDA) directed Eli Lilly and Company to include warning statements for Strattera (atomoxetine), alerting health care providers of an increased risk of suicidal thinking in children and adolescents.
September 30, 2005
MedWatch-The FDA Safety Information and Adverse Event Reporting Program